NEW YORK--(BUSINESS WIRE)--Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, today announced that the company has relocated its headquarters to the Westchester Park Center in White Plains, New York. The center will help accommodate growth and continue the expansion of research and development operations at its laboratory facilities located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.
“The Westchester Park Center will help Oligomerix sustain the growth it has made over the last several years,” said James Moe, Ph.D., MBA, President and CEO of Oligomerix. “This new location along with our recent National Institutes of Health (NIH) grant award will allow our operations to function more efficiently as we move towards clinical testing of our lead candidate for Alzheimer’s disease.”
Oligomerix recently announced a $3.19 million grant from the National Institute on Aging (NIA) at NIH. The three-year SBIR/STTR Commercialization Readiness Pilot (CRP) Program award will enable the company to further develop its small molecule tau self-association inhibitor.
“As a diverse area that is home to some of the world’s leading academic institutions, innovative scientific research centers, and Fortune 500 companies, Westchester County has been focused on bringing pioneering life science and biotech companies to the region,” said County Executive George Latimer. “We are excited to have Oligomerix join our community and look forward to providing them with the resources they need to advance their mission of bringing innovative therapies to Alzheimer’s patients who desperately need them.”
About Oligomerix’s Lead Program
Oligomerix’s lead candidate is a small molecule inhibitor of tau self-association and targets the beginning of the tau aggregation cascade. The activity of the drug translated from in vitro and cell assays to animal studies, validating the company’s screening approach. In vivo proof-of-concept studies demonstrated compound efficacy in two transgenic mouse models with tau pathology representative of AD and frontotemporal dementia. In a study recently published in the Journal of Alzheimer’s Disease, Oligomerix and the Feinstein Institutes for Medical Research at Northwell Health reported that the compound inhibited both the accumulation of self-associated tau and large tau aggregates, validating the target approach for inhibiting tau aggregation. Preliminary preclinical safety studies show the drug is well tolerated with no adverse events or behavioral abnormalities observed. The compound is being developed with an accompanying novel biomarker.
About Oligomerix, Inc.
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.
Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit http://www.oligomerix.com.
